{"success":true,"data":{"pressRelease":{"id":"161694","rtpr_id":"nGNX4RSsRz-20261006","ticker":"ENTX","exchange":"NASDAQ","all_tickers":["ENTX","FATE","JAZZ","5DT"],"title":"Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise","author":"Globe Newswire","published_at":"2026-10-06T12:00:01.180Z","article_body":"TEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:\nENTX) (“Entera” or the “Company”), a leader in the development of oral\npeptides, today announced the appointment of biopharmaceutical executive Laura\nHamill to its Board of Directors, effective December 1, 2026. Ms. Hamill\nbrings more than 35 years of global commercial, market access and business\nleadership experience across multiple therapeutic areas. She succeeds Yonatan\nMalca, who is stepping down from the Board.\n\n“I am delighted to welcome Laura to our Board as Entera enters an important\nnew chapter of late-stage clinical execution, commercial preparedness for\nEB613 and advancement of our broader pipeline,” said Miranda Toledano, Chief\nExecutive Officer of Entera. “Laura is an exceptional leader with vast\nexperience stewarding multi-billion dollar global therapeutic franchises. Her\nperspective will be invaluable as we think strategically about the potential\nof EB613 and our oral peptide platform.” “I would also like to express my\nsincere gratitude to Yonatan for his 16 years of dedicated service to\nEntera,” Ms. Toledano continued. “His leadership and commitment have\nhelped guide the Company from its inception through a period of meaningful\ngrowth and transformation.”\n\n“Entera has built a unique oral peptide pipeline with the potential to\ntransform how important therapies are delivered to patients,” said Ms.\nHamill. “I am particularly inspired by the potential of EB613 in\nosteoporosis and the opportunity to help millions of women preserve their bone\nhealth and maintain active, vibrant lives. I am excited to join the Board at\nthis important stage and support Entera as it works to advance EB613 and\nrealize the broader potential of Entera’s oral peptide platform.”\n\nMs. Hamill is a seasoned biopharmaceutical executive with more than 35 years\nof global commercial leadership experience spanning product launches, global\nfranchise development, market access and payer strategy. Most recently, she\nserved as Executive Vice President, Worldwide Commercial Operations at Gilead\nSciences, Inc., where she led an organization of approximately 2,500 employees\nresponsible for $22 billion in annual revenue and oversaw the transformation\nof the company's global commercial operations. Prior to Gilead, Ms. Hamill\nspent nearly two decades at Amgen Inc. in leadership roles of increasing\nscope. As Senior Vice President of U.S. Commercial Business Operations, she\nled commercial activities and supporting functions across Amgen's therapeutic\nareas, representing approximately 80% of Amgen’s revenue. She previously\nserved as Senior Vice President of Amgen's Intercontinental Region, overseeing\n26 countries worldwide. Earlier in her Amgen career, she held leadership roles\nincluding Vice President of International Marketing and Business Operations in\nSwitzerland and Vice President of U.S. Corporate Accounts and Reimbursement.\nMs. Hamill currently serves on the Boards of Directors of Jazz Pharmaceuticals\nplc (Nasdaq: JAZZ), BB Biotech AG and Fate Therapeutics, Inc. (Nasdaq: FATE).\nShe previously served on the boards of Acceleron Pharma Inc., Pardes\nBiosciences and Y-mAbs Therapeutics, Inc. Ms. Hamill holds a Bachelor of\nBusiness Administration in Marketing from the University of Arizona.\n\nAbout Entera\nEntera is a clinical stage company focused on developing oral peptide and\nprotein replacement therapies for significant unmet medical needs where an\noral tablet form holds the potential to transform the standard of care. The\nCompany leverages a disruptive and proprietary technology platform (N-Tab®)\nand its pipeline of first-in-class oral peptide programs. The Company’s most\nadvanced product candidate, EB613 (oral PTH(1-34)), is being developed as the\nfirst oral, osteoanabolic (bone building) once-daily tablet for osteoporosis.\nA placebo-controlled, dose-ranging Phase 2 study of EB613 tablets (n = 161)\nmet primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera\nis also developing the first oral Long Acting PTH(1-34) tablet as a\nreplacement therapy for patients with hypoparathyroidism (EB612), the first\noral oxyntomodulin, a dual targeted GLP1/glucagon peptide tablet for the\ntreatment of obesity and metabolic syndromes; and the first oral GLP-2 tablet\nas an injection-free alternative for patients suffering from rare\nmalabsorption conditions such as short bowel syndrome in collaboration with\nOPKO Health, Inc. For more information on Entera, visit www.enterabio.com or\nfollow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=SJxy9fRjag9O3vTMBobvN5gfhqu9ubOOVjBnPJSZ74WG2QSAUmGwUrrVGbWKYHzcif2F7BWWuI8Pne9mgSEjomwVsJdhvTU8IXyaKmXy4pE=),\nTwitter\n(https://www.globenewswire.com/Tracker?data=8a0wbIJcsi9BD-L7OUIa-wQxxUBnPAtK4G32Shc8MjXRWaou0ZSLkkx_fO7_0DTzj99mPv_EXVI44Z_N5dnuqA==),\nand Facebook\n(https://www.globenewswire.com/Tracker?data=aNGOEtFyDkGSpTk0wN7Q1_XTJdiUohK2xdawYOwOSzy8CS8Zo5tiqWh5sGd7s5t1F7DAHAVpP59ZOL0EC2LakODCYPI5EbwQtFM_u_4VomE=).\n\nCautionary Statement Regarding Forward Looking Statements\nVarious statements in this press release are “forward-looking statements”\nwithin the meaning of the Private Securities Litigation Reform Act of 1995.\nAll statements (other than statements of historical facts) in this press\nrelease regarding our prospects, plans, financial position, business strategy,\nclinical development activities, collaboration arrangements and expected\nfinancial and operational results are forward-looking statements. Words such\nas, but not limited to, “anticipate,” “believe,” “can,”\n“could,” “expect,” “estimate,” “design,” “goal,”\n“intend,” “may,” “might,” “objective,” “plan,”\n“predict,” “project,” “target,” “likely,” “should,”\n“will,” and “would,” or the negative of these terms and similar\nexpressions or words, identify forward-looking statements. Forward-looking\nstatements are based upon current expectations that involve risks, changes in\ncircumstances, assumptions and uncertainties. Forward-looking statements\nshould not be read as a guarantee of future performance or results and may not\nbe accurate indications of when such performance or results will be achieved.\nImportant factors that could cause actual results to differ materially from\nthose reflected in Entera’s forward-looking statements include, among\nothers: changes in the interpretation of clinical data; results of our\nclinical trials; the FDA’s interpretation and review of our results from and\nanalysis of our clinical trials; unexpected changes in our ongoing and planned\npreclinical development and clinical trials, the timing of and our ability to\nmake regulatory filings and obtain and maintain regulatory approvals for our\nproduct candidates; the potential disruption and delay of manufacturing supply\nchains; loss of available workforce resources, either by Entera or its\ncollaboration and laboratory partners; impacts to research and development or\nclinical activities that Entera may be contractually obligated to provide;\noverall regulatory timelines; the size and growth of the potential markets for\nour product candidates; the scope, progress and costs of developing Entera’s\nproduct candidates; Entera’s reliance on third parties to conduct its\nclinical trials; Entera’s ability to establish and maintain development and\ncommercialization collaborations; Entera’s operation as a development stage\ncompany with limited operating history; Entera’s competitive position with\nrespect to other products on the market or in development for the treatment of\nosteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic\nconditions and other disease categories it pursues; Entera’s ability to\ncontinue as a going concern absent access to sources of liquidity; Entera’s\nability to obtain and maintain regulatory approval for any of its product\ncandidates; Entera’s ability to comply with Nasdaq’s minimum listing\nstandards and other matters related to compliance with the requirements of\nbeing a public company in the United States; Entera’s intellectual property\nposition and its ability to protect its intellectual property; and other\nfactors that are described in the “Cautionary Statement Regarding\nForward-Looking Statements,” “Risk Factors” and “Management’s\nDiscussion and Analysis of Financial Condition and Results of Operations”\nsections of Entera’s most recent Annual Report on Form 10-K filed with the\nSEC, as well as Entera’s subsequently filed Quarterly Reports on Form 10-Q\nand Current Reports on Form 8-K. There can be no assurance that the actual\nresults or developments anticipated by Entera will be realized or, even if\nsubstantially realized, that they will have the expected consequences to, or\neffects on, Entera. Therefore, no assurance can be given that the outcomes\nstated or implied in such forward-looking statements and estimates will be\nachieved. Entera cautions investors not to rely on the forward-looking\nstatements Entera makes in this press release. The information in this press\nrelease is provided only as of the date of this press release, and Entera\nundertakes no obligation to update or revise publicly any forward-looking\nstatements, whether as a result of new information, future events or\notherwise, except to the extent required by law.\n\nCompany Contact:\nIR@enterabio.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/cad5c2b9-1536-4364-aa1b-6b8216d3658f)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX4RSsRz-20261006","title":"Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise","author":"Globe Newswire","ticker":"ENTX","created":"2026-10-06T12:00:01.180Z","tickers":["ENTX","FATE","JAZZ","5DT"],"exchange":"NASDAQ","article_body":"TEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:\nENTX) (“Entera” or the “Company”), a leader in the development of oral\npeptides, today announced the appointment of biopharmaceutical executive Laura\nHamill to its Board of Directors, effective December 1, 2026. Ms. Hamill\nbrings more than 35 years of global commercial, market access and business\nleadership experience across multiple therapeutic areas. She succeeds Yonatan\nMalca, who is stepping down from the Board.\n\n“I am delighted to welcome Laura to our Board as Entera enters an important\nnew chapter of late-stage clinical execution, commercial preparedness for\nEB613 and advancement of our broader pipeline,” said Miranda Toledano, Chief\nExecutive Officer of Entera. “Laura is an exceptional leader with vast\nexperience stewarding multi-billion dollar global therapeutic franchises. Her\nperspective will be invaluable as we think strategically about the potential\nof EB613 and our oral peptide platform.” “I would also like to express my\nsincere gratitude to Yonatan for his 16 years of dedicated service to\nEntera,” Ms. Toledano continued. “His leadership and commitment have\nhelped guide the Company from its inception through a period of meaningful\ngrowth and transformation.”\n\n“Entera has built a unique oral peptide pipeline with the potential to\ntransform how important therapies are delivered to patients,” said Ms.\nHamill. “I am particularly inspired by the potential of EB613 in\nosteoporosis and the opportunity to help millions of women preserve their bone\nhealth and maintain active, vibrant lives. I am excited to join the Board at\nthis important stage and support Entera as it works to advance EB613 and\nrealize the broader potential of Entera’s oral peptide platform.”\n\nMs. Hamill is a seasoned biopharmaceutical executive with more than 35 years\nof global commercial leadership experience spanning product launches, global\nfranchise development, market access and payer strategy. Most recently, she\nserved as Executive Vice President, Worldwide Commercial Operations at Gilead\nSciences, Inc., where she led an organization of approximately 2,500 employees\nresponsible for $22 billion in annual revenue and oversaw the transformation\nof the company's global commercial operations. Prior to Gilead, Ms. Hamill\nspent nearly two decades at Amgen Inc. in leadership roles of increasing\nscope. As Senior Vice President of U.S. Commercial Business Operations, she\nled commercial activities and supporting functions across Amgen's therapeutic\nareas, representing approximately 80% of Amgen’s revenue. She previously\nserved as Senior Vice President of Amgen's Intercontinental Region, overseeing\n26 countries worldwide. Earlier in her Amgen career, she held leadership roles\nincluding Vice President of International Marketing and Business Operations in\nSwitzerland and Vice President of U.S. Corporate Accounts and Reimbursement.\nMs. Hamill currently serves on the Boards of Directors of Jazz Pharmaceuticals\nplc (Nasdaq: JAZZ), BB Biotech AG and Fate Therapeutics, Inc. (Nasdaq: FATE).\nShe previously served on the boards of Acceleron Pharma Inc., Pardes\nBiosciences and Y-mAbs Therapeutics, Inc. Ms. Hamill holds a Bachelor of\nBusiness Administration in Marketing from the University of Arizona.\n\nAbout Entera\nEntera is a clinical stage company focused on developing oral peptide and\nprotein replacement therapies for significant unmet medical needs where an\noral tablet form holds the potential to transform the standard of care. The\nCompany leverages a disruptive and proprietary technology platform (N-Tab®)\nand its pipeline of first-in-class oral peptide programs. The Company’s most\nadvanced product candidate, EB613 (oral PTH(1-34)), is being developed as the\nfirst oral, osteoanabolic (bone building) once-daily tablet for osteoporosis.\nA placebo-controlled, dose-ranging Phase 2 study of EB613 tablets (n = 161)\nmet primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera\nis also developing the first oral Long Acting PTH(1-34) tablet as a\nreplacement therapy for patients with hypoparathyroidism (EB612), the first\noral oxyntomodulin, a dual targeted GLP1/glucagon peptide tablet for the\ntreatment of obesity and metabolic syndromes; and the first oral GLP-2 tablet\nas an injection-free alternative for patients suffering from rare\nmalabsorption conditions such as short bowel syndrome in collaboration with\nOPKO Health, Inc. For more information on Entera, visit www.enterabio.com or\nfollow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=SJxy9fRjag9O3vTMBobvN5gfhqu9ubOOVjBnPJSZ74WG2QSAUmGwUrrVGbWKYHzcif2F7BWWuI8Pne9mgSEjomwVsJdhvTU8IXyaKmXy4pE=),\nTwitter\n(https://www.globenewswire.com/Tracker?data=8a0wbIJcsi9BD-L7OUIa-wQxxUBnPAtK4G32Shc8MjXRWaou0ZSLkkx_fO7_0DTzj99mPv_EXVI44Z_N5dnuqA==),\nand Facebook\n(https://www.globenewswire.com/Tracker?data=aNGOEtFyDkGSpTk0wN7Q1_XTJdiUohK2xdawYOwOSzy8CS8Zo5tiqWh5sGd7s5t1F7DAHAVpP59ZOL0EC2LakODCYPI5EbwQtFM_u_4VomE=).\n\nCautionary Statement Regarding Forward Looking Statements\nVarious statements in this press release are “forward-looking statements”\nwithin the meaning of the Private Securities Litigation Reform Act of 1995.\nAll statements (other than statements of historical facts) in this press\nrelease regarding our prospects, plans, financial position, business strategy,\nclinical development activities, collaboration arrangements and expected\nfinancial and operational results are forward-looking statements. Words such\nas, but not limited to, “anticipate,” “believe,” “can,”\n“could,” “expect,” “estimate,” “design,” “goal,”\n“intend,” “may,” “might,” “objective,” “plan,”\n“predict,” “project,” “target,” “likely,” “should,”\n“will,” and “would,” or the negative of these terms and similar\nexpressions or words, identify forward-looking statements. Forward-looking\nstatements are based upon current expectations that involve risks, changes in\ncircumstances, assumptions and uncertainties. Forward-looking statements\nshould not be read as a guarantee of future performance or results and may not\nbe accurate indications of when such performance or results will be achieved.\nImportant factors that could cause actual results to differ materially from\nthose reflected in Entera’s forward-looking statements include, among\nothers: changes in the interpretation of clinical data; results of our\nclinical trials; the FDA’s interpretation and review of our results from and\nanalysis of our clinical trials; unexpected changes in our ongoing and planned\npreclinical development and clinical trials, the timing of and our ability to\nmake regulatory filings and obtain and maintain regulatory approvals for our\nproduct candidates; the potential disruption and delay of manufacturing supply\nchains; loss of available workforce resources, either by Entera or its\ncollaboration and laboratory partners; impacts to research and development or\nclinical activities that Entera may be contractually obligated to provide;\noverall regulatory timelines; the size and growth of the potential markets for\nour product candidates; the scope, progress and costs of developing Entera’s\nproduct candidates; Entera’s reliance on third parties to conduct its\nclinical trials; Entera’s ability to establish and maintain development and\ncommercialization collaborations; Entera’s operation as a development stage\ncompany with limited operating history; Entera’s competitive position with\nrespect to other products on the market or in development for the treatment of\nosteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic\nconditions and other disease categories it pursues; Entera’s ability to\ncontinue as a going concern absent access to sources of liquidity; Entera’s\nability to obtain and maintain regulatory approval for any of its product\ncandidates; Entera’s ability to comply with Nasdaq’s minimum listing\nstandards and other matters related to compliance with the requirements of\nbeing a public company in the United States; Entera’s intellectual property\nposition and its ability to protect its intellectual property; and other\nfactors that are described in the “Cautionary Statement Regarding\nForward-Looking Statements,” “Risk Factors” and “Management’s\nDiscussion and Analysis of Financial Condition and Results of Operations”\nsections of Entera’s most recent Annual Report on Form 10-K filed with the\nSEC, as well as Entera’s subsequently filed Quarterly Reports on Form 10-Q\nand Current Reports on Form 8-K. There can be no assurance that the actual\nresults or developments anticipated by Entera will be realized or, even if\nsubstantially realized, that they will have the expected consequences to, or\neffects on, Entera. Therefore, no assurance can be given that the outcomes\nstated or implied in such forward-looking statements and estimates will be\nachieved. Entera cautions investors not to rely on the forward-looking\nstatements Entera makes in this press release. The information in this press\nrelease is provided only as of the date of this press release, and Entera\nundertakes no obligation to update or revise publicly any forward-looking\nstatements, whether as a result of new information, future events or\notherwise, except to the extent required by law.\n\nCompany Contact:\nIR@enterabio.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/cad5c2b9-1536-4364-aa1b-6b8216d3658f)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-06T12:00:01.558093816Z","server_sent_at_ms":1791288001558},"received_at":"2026-10-06T12:00:01.610Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}